Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Although inadequate antimicrobial therapy has been demonstrated in multiple studies to increase the risk for death in bacterial infections, few data investigating the effect of antifungal therapy on outcome of serious fungal disease are available. We sought to assess the adequacy of empirical therapy and its effect on mortality in invasive Candida species infections. METHODS: Population-based surveillance of all patients with Candida spp. cultured from blood and/or cerebrospinal fluid was conducted. Adequacy of empirical therapy was assessed according to published guidelines. RESULTS: During a 5 year period, 207 patients had an invasive Candida spp. infection identified; in 199 cases (96%) adequate data were available for assessment of treatment and outcome at hospital discharge. One hundred and three (52%) cases were due to Candida albicans, 44 (22%) were due to Candida glabrata and the remainder were due to other species. Between the time of culture draw and reporting of a positive culture, only 64 (32%) patients were treated with empirical therapy; this was deemed adequate in 51 (26%). Patients who received adequate empirical therapy had a significant decrease in crude mortality [14/51 (27%) versus 68/148 (46%); risk ratio 0.60 (95% confidence interval 0.37-0.96); P = 0.02]. After adjusting for age and the need for intensive care unit admission in logistic regression analysis, the use of adequate empirical therapy was independently associated with a reduced risk for death [odds ratio 0.46 (95% confidence interval 0.22-1.00); P = 0.05]. CONCLUSIONS: Adequate empirical therapy is used in a minority of patients with invasive Candida spp. infections but is associated with improved survival.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although retrospective studies have suggested that empiric antifungal therapy might improve survival for select high-risk patients [28]”
From Treatment practices for adults with candidemia at 9 active surveillance sites—United States, 2017–2018. (2021) · cites this paper as [28]
Citations
Cites
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
Kumar, A., Roberts, D., Wood, K. E., Light, B., Parrillo, J. E., Sharma, S., Suppes, R., Feinstein, D., Zanotti, S., Taiberg, L., et al. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000217961.75225.e9 · Cited by 6,109 · cited 2×
“Lastly, Kumar et al. 28 were able to demonstrate an increase in mortality with each hour of treatment delay in fungal septic shock (RR 1.06).”
BackgroundInfluentialInadequate Antimicrobial Treatment of Infections
Kollef, M. H., Sherman, G., Ward, S., & Fraser, V. J. (1999) · Chest · doi:10.1378/chest.115.2.462 · Cited by 1,805
Ibrahim, E. H., Sherman, G., Ward, S., Fraser, V. J., & Kollef, M. H. (2000) · Chest · doi:10.1378/chest.118.1.146 · Cited by 1,779 · cited 2×
“Inappropriate initial antimicrobial therapies have been linked with increased patient fatality.(14) – 17,24,25 Subsequent corrected regimens following microbiological identification of the pathogen have not been associated with improved patient survival, thus highlighting the critical importance of correct initial ant…”
BackgroundGuidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440 · cited 2×
“Accordingly, many experts advocate early empirical antifungal therapies in patients deemed high risk.(2,20,21) However, no studies to date have specifically addressed the role of empirical antifungal therapies on patient outcome.”
BackgroundMethodNosocomial Bloodstream Infections in United States Hospitals: A Three‐Year Analysis
Edmond, M. B., Wallace, S. E., McClish, D. K., Pfaller, M. A., Jones, R. N., & Wenzel, R. P. (1999) · Clinical Infectious Diseases · doi:10.1086/520192 · Cited by 1,387
Morrell, M., Fraser, V. J., & Kollef, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3640-3645.2005 · Cited by 1,286
Garey, K. W., Rege, M., Pai, M. P., Mingo, D. E., Suda, K. J., Turpin, R. S., & Bearden, D. T. (2006) · Clinical Infectious Diseases · doi:10.1086/504810 · Cited by 1,171 · cited 3×
“Garey et al. 18 further demonstrated in a multicentre retrospective study that for each successive day of delay in receipt of fluconazole treatment there was an increase in patient mortality.”
BackgroundHospital-Acquired Candidemia: The Attributable Mortality and Excess Length of Stay
Wey, S. B. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.1988.00380120094019 · Cited by 831
Trick, W. E., Fridkin, S. K., Edwards, J. R., Hajjeh, R. A., Gaynes, R. P., & Hospitals, T. N. N. I. S. S. (2002) · Clinical Infectious Diseases · doi:10.1086/342300 · Cited by 660
Harbarth, S., Garbino, J., Pugin, J., Romand, J. A., Lew, D., & Pittet, D. (2003) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.07.005 · Cited by 637
Inadequate Antimicrobial Treatment: An Important Determinant of Outcome for Hospitalized Patients
Kollef, M. H. (2000) · Clinical Infectious Diseases · doi:10.1086/314079 · Cited by 635
Pfaller, M. A., Diekema, D. J., Jones, R. N., Sader, H. S., Fluit, A. C., Hollis, R. J., Messer, S. A., & The SENTRY Participant Group (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.9.3254-3259.2001 · Cited by 521 · cited 2×
“Candida species are among the most common causes of nosocomial bloodstream infection.(1) Furthermore, invasive candidiasis is increasingly commonplace owing to the increasing use of intravascular catheters, broad-spectrum antibacterial agents and enhanced immunosuppression.”
BackgroundTortorano, A. M., Peman, J., Bernhardt, H., Klingspor, L., Kibbler, C. C., Faure, O., Biraghi, E., Canton, E., Zimmermann, K., Seaton, S., et al. (2004) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1103-y · Cited by 509 · cited 1×
“In addition to an attributable mortality of 40–49%, invasive candidiasis is associated with increased length of stay(6,7) and increased healthcare expenditure.(8,9) Risk factors for invasive candidiasis and mortality secondary to invasive candidiasis are well described.”
BackgroundThe Influence of Mini-BAL Cultures on Patient Outcomes
MD, M. H. K., & Ward, S. (1998) · Chest · doi:10.1378/chest.113.2.412 · Cited by 494
The Value of Routine Microbial Investigation in Ventilator-Associated Pneumonia
RELLO, J., GALLEGO, M., MARISCAL, D., SOÑORA, R., & VALLES, J. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.156.1.9607030 · Cited by 467
Diekema, D. J., Messer, S. A., Brueggemann, A. B., Coffman, S. L., Doern, G. V., Herwaldt, L. A., & Pfaller, M. A. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.4.1298-1302.2002 · Cited by 385
The Impact of Candidemia on Length of Hospital Stay, Outcome, and Overall Cost of Illness
Rentz, A. M., Halpern, M. T., & Bowden, R. (1998) · Clinical Infectious Diseases · doi:10.1086/514955 · Cited by 310 · cited 1×
“In addition to an attributable mortality of 40–49%, invasive candidiasis is associated with increased length of stay(6,7) and increased healthcare expenditure.(8,9) Risk factors for invasive candidiasis and mortality secondary to invasive candidiasis are well described.”
BackgroundDupont, H., Mentec, H., Sollet, J. P., & Bleichner, G. (2001) · Intensive Care Medicine · doi:10.1007/s001340000640 · Cited by 309
Viudes, A., Pemán, J., Cantón, E., Úbeda, P., López-Ribot, J., & Gobernado, M. (2002) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-002-0822-1 · Cited by 250
Appropriateness and delay to initiate therapy in ventilator-associated pneumonia
Luna, C. M., Aruj, P., Niederman, M. S., Garzón, J., Violi, D., Prignoni, A., Ríos, F., Baquero, S., & Gando, S. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00049105 · Cited by 246
Management of candidiasis Management of Candida species infections in critically ill patients
Eggimann, P., Garbino, J., & Pittet, D. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00831-4 · Cited by 234
Pappas, P. G. (2006) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2006.07.004 · Cited by 227
Systemic candidiasis in intensive care units: A multicenter, matched-cohort study
Leleu, G., Aegerter, P., & Guidet, B. (2002) · Journal of Critical Care · doi:10.1053/jcrc.2002.35815 · Cited by 160
Leinberger, D. M., Schumacher, U., Autenrieth, I. B., & Bachmann, T. T. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.10.4943-4953.2005 · Cited by 155
The global epidemiology of invasive Candida infections—is the tide turning?
Hobson, R. P. (2003) · Journal of Hospital Infection · doi:10.1016/j.jhin.2003.08.012 · Cited by 137
Risk factors for fatal candidemia caused by Candida albicans and non-albicans Candida species
Cheng, M.-F., Yang, Y.-L., Yao, T.-J., Lin, C.-Y., Liu, J.-S., Tang, R.-B., Yu, K.-W., Fan, Y.-H., Hsieh, K.-S., Ho, M., et al. (2005) · BMC Infectious Diseases · doi:10.1186/1471-2334-5-22 · Cited by 136
Invasive Candida species infections: a 5 year population-based assessment
Laupland, K. B., Gregson, D. B., Church, D. L., Ross, T., & Elsayed, S. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki258 · Cited by 130
Self-citationGolan, Y., Wolf, M. P., Pauker, S. G., Wong, J. B., & Hadley, S. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-12-200512200-00004 · Cited by 95
Candidosis in the intensive care unit: a 20-year survey
Tortorano, A. M., Caspani, L., Rigoni, A. L., Biraghi, E., Sicignano, A., & Viviani, M. A. (2004) · Journal of Hospital Infection · doi:10.1016/j.jhin.2004.01.017 · Cited by 76
Bu, R., Sathiapalan, R. K., Ibrahim, M. M., Al-Mohsen, I. Z., Almodavar, E., Gutiérrez, M. I., & Bhatia, K. G. (2005) · Journal of Medical Microbiology · doi:10.1099/jmm.0.45856-0 · Cited by 64
Kasai, M., Francesconi, A., Petraitiene, R., Petraitis, V., Kelaher, A. M., Kim, H.-S., Meletiadis, J., Sein, T., Bacher, J., & Walsh, T. J. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.1.143-150.2006 · Cited by 60
Cited by
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
Cornely, O. A., Bassetti, M., Calandra, T., Garbino, J., Kullberg, B. J., Lortholary, O., Meersseman, W., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12039 · Cited by 1,217
Kumar, A., Ellis, P., Arabi, Y., Roberts, D., Light, B., Parrillo, J. E., Dodek, P., Wood, G., Kumar, A., Simon, D., et al. (2009) · Chest · doi:10.1378/chest.09-0087 · Cited by 1,187
Epidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
Leroy, O., Gangneux, J.-P., Montravers, P., Mira, J.-P., Gouin, F., Sollet, J.-P., Carlet, J., Reynes, J., Rosenheim, M., Regnier, B., et al. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e31819efac0 · Cited by 535
Metadata
- Authors
- Parkins, M. D., Sabuda, D. M., Elsayed, S., & Laupland, K. B.
- Affiliations
- University of Calgary (CA)
- Corresponding author
- Laupland, Kevin B.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-06-18
- Volume
- 60
- Issue
- 3
- Pages
- 613-618
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2137351193
- Semantic Scholar
- 80b38a8f43278681a310601609c65ad32cfe938e
- Cited by
- 229
- References
- 32
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 2 · 2023: 1 · 2022: 7 · 2021: 5 · 2020: 6 · 2019: 9 · 2018: 4 · 2017: 14 · 2016: 15 · 2015: 10 · 2014: 17 · 2013: 20 · 2012: 17
- FWCI
- 13.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Antimicrobial Chemotherapy (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Keywords
- invasive candidiasis, empirical antifungal therapy, treatment adequacy, mortality, Candida albicans, Candida glabrata, fungemia, cerebrospinal fluid culture, guideline adherence
- MeSH terms
- Adult, Aged, Aged, 80 and over, Alberta, Analysis of Variance, Antifungal Agents, Calibration, Candida, Candidiasis, Female, Humans, Male, Microbial Sensitivity Tests, Middle Aged, Terminology as Topic, Risk Factors, Cohort Studies, Logistic Models, Odds Ratio, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.